AI-Generated Summary

The Indian Health Ministry is investigating a batch of Coldrif Cough Syrup, manufactured by Sresan Pharma, found to contain dangerous levels of diethylene glycol (DEG) after being linked to the deaths of nine children. This incident, following a previous WHO report on Indian cough syrups, raises significant concerns about quality control and regulatory oversight within the country's pharmaceutical industry. Authorities have launched inspections across multiple states to address these lapses and prevent future tragedies.

In a nutshell

This incident underscores the critical importance of stringent quality control and robust regulatory enforcement in pharmaceutical manufacturing, especially for products destined for vulnerable populations. It highlights the ongoing challenges faced by India's pharmaceutical industry in maintaining global standards and rebuilding trust following prior controversies.

Source: The Hindu Business Line